---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039180"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:18:43.871608+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma shareholders approve reverse stock split and reelect directors

## Summary
- All 7 director nominees elected; Eric Ende received 57.9M for, 10.1M withheld; 59.1M broker non-votes.
- Say-on-pay proposal approved: 53.3M for, 12.0M against, 2.7M abstain.
- Ratification of EisnerAmper as auditor passed: 121.9M for, 3.1M against, 2.1M abstain.
- Amendment to effect reverse stock split (1:2 to 1:50) and reduce authorized shares to 250M approved: 93.0M for, 31.1M against.
- Total shares represented at meeting: 127.1M, or 58.5% of outstanding common stock.

## SEC filing metadata
- accession: 0001493152-23-039180
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039180/0001493152-23-039180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039180/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039180
- JSON: https://secwatch.observer/filing/0001493152-23-039180.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039180.txt

## Key facts
- Shareholder Votes
  Matinas BioPharma Holdings, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-2 to 1-for-50 and reduce authorized common shares to 250,000,000 at the 2023-11-01 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-11-01
  source text: Our stockholders approved an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-50, with such reverse stock split to be effected at such ratio, time and date, if at all, as determined by our Board of Directors in its sole discretion, and simultaneously with the reverse stock split, reduce the total number of authorized shares of common stock to 250,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039180/0001493152-23-039180-index.htm
- Shareholder Votes
  Matinas BioPharma Holdings, Inc. shareholders approved Election of seven directors to serve until the 2024 annual meeting at the 2023-11-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-11-01
  source text: Our stockholders elected the following individuals to serve on our board of directors until the annual meeting of shareholders to be held in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039180/0001493152-23-039180-index.htm
- Shareholder Votes
  Matinas BioPharma Holdings, Inc. shareholders approved Advisory approval of the compensation of the named executive officers at the 2023-11-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-11-01
  source text: Our stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039180/0001493152-23-039180-index.htm
- Shareholder Votes
  Matinas BioPharma Holdings, Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-11-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-11-01
  source text: Our stockholders approved the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039180/0001493152-23-039180-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.